Trial
NCT03750760
Early Alirocumab to Reduce LDL-C in Myocardial Infarction
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Imperial College London
Collaborators
Regeneron Pharmaceuticals; Baim Institute for Clinical Research
Condition
Myocardial Infarction
Intervention
Alirocumab
Why stopped
Changes in funding decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-06-13